Overview

Reduced Intensity Conditioning Transplant Using Haploidentical Donors

Status:
Completed
Trial end date:
2020-12-28
Target enrollment:
Participant gender:
Summary
This trial will evaluate the safety and efficacy of a reduced intensity allogeneic HSCT from partially HLA-mismatched first-degree relatives utilizing PBSC as the stem cell source. The primary objective of the study is to estimate the incidence of graft rejection and acute GVHD. A secondary objective will be to estimate the incidence of the relapse, NRM, OS, chronic GVHD and EFS.
Phase:
Phase 2
Details
Lead Sponsor:
Northside Hospital, Inc.
Collaborator:
Blood and Marrow Transplant Group of Georgia
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Melphalan